Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Non-Current Debt (2016 - 2020)

Amicus Therapeutics (FOLD) has disclosed Non-Current Debt for 10 consecutive years, with $147.8 million as the latest value for Q2 2020.

  • For the quarter ending Q2 2020, Non-Current Debt rose 0.57% year-over-year to $147.8 million, compared with a TTM value of $147.8 million through Jun 2020, up 0.57%, and an annual FY2019 reading of $147.4 million, changed 0.44% over the prior year.
  • Non-Current Debt was $147.8 million for Q2 2020 at Amicus Therapeutics, roughly flat from $147.6 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $147.8 million in Q2 2020 and bottomed at $21.9 million in Q2 2016.
  • Average Non-Current Debt over 4 years is $116.5 million, with a median of $146.8 million recorded in 2019.
  • The sharpest move saw Non-Current Debt soared 318.21% in 2016, then grew 0.37% in 2019.
  • Year by year, Non-Current Debt stood at $44.0 million in 2016, then skyrocketed by 233.13% to $146.7 million in 2018, then increased by 0.44% to $147.4 million in 2019, then rose by 0.31% to $147.8 million in 2020.
  • Business Quant data shows Non-Current Debt for FOLD at $147.8 million in Q2 2020, $147.6 million in Q1 2020, and $147.4 million in Q4 2019.